CN1748671A - Slow releasing injection containing anti-mitosis medicine - Google Patents
Slow releasing injection containing anti-mitosis medicine Download PDFInfo
- Publication number
- CN1748671A CN1748671A CN 200510044519 CN200510044519A CN1748671A CN 1748671 A CN1748671 A CN 1748671A CN 200510044519 CN200510044519 CN 200510044519 CN 200510044519 A CN200510044519 A CN 200510044519A CN 1748671 A CN1748671 A CN 1748671A
- Authority
- CN
- China
- Prior art keywords
- slow
- injection
- colchicine
- acid
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The slow releasing injection containing antimiotic medicine belongs to the field of slow releasing anticancer medicine technology. The injection includes the components of anticancer medicine, slow releasing supplementary material, suspending agent and/or solvent. The anticancer medicine includes cytochalasin, colchicines, beta-naphthol, acodazole, giracodazole, nocodazole or other antimiotic medicine; the slow releasing supplementary material is polylactic acid, glycolic acid-hydroxyacetic acid copolymer, EVA, polifeprosan or their composition; the suspending agent is carboxymethyl cellulose, mannitol, etc.; the solvent is selected from distilled water, injection water, anhydrous alcohol, etc. The slow releasing anticancer injection may be injected in different modes and has reduced systemic toxic reaction, raised local medicine concentration and raised treating effect.
Description
(1) technical field
The present invention relates to a kind of slow releasing injection that contains anti-mitosis medicine, belong to technical field of pharmaceuticals.
(2) background technology
Anti-mitosis medicine has been widely used in the treatment of multiple malignant tumor as chemotherapeutics commonly used, and has obtained comparatively significantly action effect.Yet, discover that further unsuitable administration usually causes the generation of toleration, finally cause the failure for the treatment of.Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, therefore, conventional chemotherapy, be difficult to tumor by local and form effective drug level, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 1998 69 phase 76-82 pages or leaves (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82), improve the restriction that dosage is subjected to general reaction again merely.Medicine is implanted the problem may solve drug level to a certain extent, yet medicine implant surgery operation is complicated, and is traumatic big, the various complication such as, infection hemorrhage except that easily causing, immunity reduction, also can cause or quicken the diffusion and the transfer of tumor.In addition, the preparation of perioperatively itself and rehabilitation require usually to influence the enforcement and the process of conventional therapies such as radiotherapy and chemotherapy.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of slow releasing injection that contains anti-mitosis medicine is provided.
Anti-cancer medicine sustained-release injection of the present invention comprises sustained-release microparticle, suspending agent and/or solvent, and sustained-release microparticle is made up of 1%-80% anti-mitosis medicine and 20-99% slow-release auxiliary material, all is weight percentage.
Above-mentioned anti-mitosis medicine is selected from cytochalasin (podophyllotoxin), Datelliptium Chloride, ellipticine, 2-Methylellipticine, mitoclomine (Mitoclomine), mitoflaxone [Mitoflaxone], mitoguazone [Mitoguazone], mitonafide [Mitonafide], mitopodozide [Mitopodozide], mitoquidone [Mitoquidone], mitosper [Mitosper], mitotane [Mitotane], mitotenamine [Mitotenamine], mitozolomide [Mitozolomide], Flavone acetic acid, colchicine, Salicylate (colchisal), colchiceinamide [Colchiceinamide], colchicine [Colchicine], 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a (colchiceine), sulfo--colchicine (thio-colchicine), Demecolcine [Demecolcine], Colchiceinamidum, Colchicine, B cytochalasin B (cytochalasins) is (as A-E, H, J), carbaryl (sevin, carbaryl), naphthols (naphthol), alpha-Naphthol (1-naphthol), betanaphthol (2-naphthol), alpha-phosphate naphthols (1-naphthylphosphate), acodazole (Acodazole), procodazole [Procodazole], giracodazole [Giracodazole], nocodazole (nocodazole), one of malonic acid (malonate) and malonate or its combination; Wherein, preferred colchicine, Colchicine, nocodazole, giracodazole, acodazole, procodazole, B cytochalasin B, mitotenamine, naphthols or betanaphthol.
Anti-mitosis medicine will make tumor cell stop at the different links of cell cycle.Anti-mitosis medicine shared percentage by weight in sustained-release microparticle is also decided because of concrete condition, can be good with 1%-50% from 1%-80%, with 5%-40% for most preferably.
Slow-release auxiliary material is selected from mixture, the ethylene vinyl acetate copolymer (EVAc), poly-(1 of the copolymer (PLGA), polylactic acid (PLA) of polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic acid and hydroxyacetic acid and the copolymer (PLGA) of polyglycolic acid and hydroxyacetic acid, 3-two (to the carboxyl phenoxy group) propane-decanedioic acid) one of (p (CPP-SA), polifeprosan), xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin and white tempera or its combination.
Polylactic acid in the above-mentioned slow-release auxiliary material (PLA) molecular weight peak value can be, but is not limited to 5,000～100,000, and with 20,000～60,000 is preferred, and with 30,000～50,000 for most preferably; The molecular weight of polyglycolic acid (PGA) can be, but is not limited to 5,000～100,000, and with 20,000～60,000 is preferred, and with 30,000～50,000 for most preferably; The molecular weight of the copolymer of glycolic and hydroxyacetic acid (PLGA) can be, but is not limited to 5,000～100,000, but with 20,000～60, and 000 is preferred, and with 30,000～50,000 for most preferably; The blend weight ratio of glycolic and hydroxyacetic acid is 10/90-90/10, in poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid) (p (CPP-SA), polifeprosan), to the weight ratio 10/90-90/10 of carboxy phenyl propane (p-CPP) with certain herbaceous plants with big flowers diacid (SA), preferred 25/75-75/25.
Suspending agent is selected from one of carboxymethyl cellulose, sodium carboxymethyl cellulose, glycerol, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, polysorbas20 or Tween 80 or its combination.
When containing suspending agent and solvent simultaneously, suspending agent and solvent are formed special solvent, also claim the injection system, the content of suspending agent wherein in solvent is 0.1mg/ml-20mg/ml, the kind that depends on used suspending agent, as carboxymethyl cellulose or sodium carboxymethyl cellulose is that the volume weight percentage ratio of solvent can be preferred with 0.5-3% from 0.1-5%, and 1-2% is for most preferably.And the content of tween in solvent is 0.1mg/ml-1mg/ml, and mannitol or the sorbitol content in solvent is 10mg/ml-20mg/ml.
The sustained-release microparticle of above-mentioned slow releasing injection can prepare with some kinds of methods, as, but be not limited to (i) fusion method: pharmaceutic adjuvant is directly pulverized with medicine mixed, melt, cool off the preparation slow-releasing granules then; (ii) dissolution method: pharmaceutic adjuvant and medicine dissolution in organic solvent, remove solvent then and prepare sustained-release micro-spheres; (iii) spray drying method for preparation microsphere; (iv) freezing (drying) comminuting method is made micropowder; (v) dissolution method is made micropowder in conjunction with freezing (drying) comminuting method; (vi) liposome bag medicine method and (vii) preparation such as emulsion process sustained-release micro-spheres.The particle size range of made microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Sustained-release microparticle can be different shape, as, but be not limited to microgranule, granule, spherical piller, microsphere or micropowder.Be to regulate drug releasing rate, the composition and the proportioning that can change the monomer component of polymer or molecular weight, interpolation or regulate pharmaceutic adjuvant are added any one or multiple other pharmaceutic adjuvant as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function, and its content is decided because of concrete condition.Slow release or pharmaceutic adjuvant are in Luo Mingsheng and Gao Tianhui chief editor's " pharmaceutic adjuvant complete works " the 123rd page, had a detailed description in " pharmaceutics " People's Health Publisher in May, 85 version of chief editors such as Sichuan science tech publishing house in March, 1993 version and Tu Xide, in addition, Chinese patent (application number 96115937.5,91109723.6,9710703.3,01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerate some pharmaceutic adjuvant, comprised filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, cross-linking agent, the binding agent, excipient or blocker.Above pharmaceutic adjuvant has has multiple action, and therefore the material of the same race that has is listed in different classifications.
The available holder of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
Slow-releasing system can separate the packing respectively of independent sterilization back, storage, suspendible, injection again during use with the injection system; Also slow-releasing system can be mixed back sterilization, packing with a certain proportion of suspending agent, it is suspended in the common solvent or special solvent of the packing of separately sterilizing during use.Used common solvent refers to clinical injection commonly used, as, but be not limited to, the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt is as phosphate or carbonate buffer solution etc.Special solvent is the common solvent that contains a kind of or several suspending agents; Slow-releasing system is sterilized after also can being suspended in the injection system, packing, and the time spent direct injection can add a certain amount of antiseptic in such cases.
Slow releasing injection of the present invention can be further divided into gel-type slow releasing injection, solution-type slow releasing injection, suspension type slow releasing injection, microcapsule-type slow releasing injection, microspheric slow releasing injection, block copolymer micelle injection or liposome slow releasing injection.More than in the multiple slow releasing injection, preferred suspension type slow releasing injection, gel-type slow releasing injection, microspheric slow releasing injection, block copolymer micelle injection.
Wherein, the suspension type slow releasing injection is the preparation that the sustained-release microparticle that will contain anticancer component is suspended in gained in the injection.Gel-type slow releasing injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), add medicine miscible with it (or suspendible) back again and form flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.The microspheric slow releasing injection comprises microparticulate preparations such as microsphere, sub-micro ball, microemulsion, nanosphere, liposome or gel, and used pharmaceutical carrier is above-mentioned any one or its combination.The block copolymer micelle injection is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is 1,000-15,000 Polyethylene Glycol (PEG) are as the hydrophilic block of micelle copolymer, and preferred biological degradation polyalcohol is (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1,500-25,000) as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.
In above-mentioned all kinds of slow releasing injection with the suspension type slow releasing injection for most preferably, the suspension type slow releasing injection is the preparation that the sustained-release microparticle that will contain anticancer component is suspended in gained in the injection, used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material.The mode that suspends is divided into multiple, but based on following three kinds, the one, the sustained-release microparticle of pastille is packed with suspending agent, before injection, it is suspended in the common solvent, i.e. " sustained-release microparticle and suspending agent+common solvent " scheme; The 2nd, the sustained-release microparticle of pastille is packed separately, before injection, it is suspended in the special solvent, i.e. " sustained-release microparticle+special solvent " scheme; The 3rd, with the packing of behind suspending agent and common solvent suspendible, sterilizing of the sustained-release microparticle of pastille, time spent direct injection.
Slow-releasing anticarcinogen injection of the present invention, component are 20mg anti-mitosis medicine, 80mg slow-release auxiliary material and 1mg suspending agent.Wherein, anti-mitosis medicine is for being colchicine, acodazole, procodazole, giracodazole or nocodazole; Slow-release auxiliary material is one of copolymer, ethylene vinyl acetate copolymer and polifeprosan of polylactic acid, glycolic and hydroxyacetic acid or its combination; Suspending agent is selected from one of carboxymethyl cellulose, sodium carboxymethyl cellulose, glycerol, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, polysorbas20 or Tween 80 or its combination.
Slow-releasing anticarcinogen injection of the present invention, component are 30mg anti-mitosis medicine, 70mg slow-release auxiliary material and 10ml solvent.Wherein, anti-mitosis medicine is for being colchicine, acodazole, procodazole, giracodazole or nocodazole; Slow-release auxiliary material is one of copolymer, ethylene vinyl acetate copolymer and polifeprosan of polylactic acid, glycolic and hydroxyacetic acid or its combination; Solvent is selected from distilled water, water for injection, physiology towards liquid, dehydrated alcohol, phosphate or carbonate buffer solution.
Slow-releasing anticarcinogen injection of the present invention, component are 20mg anti-mitosis medicine, 80mg slow-release auxiliary material, 2mg suspending agent and 10ml solvent.Wherein, anti-mitosis medicine is colchicine, acodazole, procodazole, giracodazole or nocodazole; Slow-release auxiliary material is one of copolymer, ethylene vinyl acetate copolymer and polifeprosan of polylactic acid, glycolic and hydroxyacetic acid or its combination; Solvent is selected from distilled water, water for injection, physiology towards liquid, dehydrated alcohol, phosphate or carbonate buffer solution.
The purpose that slow releasing injection of the present invention is used suspending agent is the pastille slow-release microsphere that effectively suspends, thereby is beneficial to injection.
The used pharmaceutic adjuvant of slow releasing injection is above-mentioned a kind of or several adjuvants, can import in the body cavity, in the tumor or tumor all; The gel-type slow releasing injection is biological degradation polyalcohol PLA, PLGA, hyaluronic acid, chrondroitin, collagen protein, gelatin, albumin etc. to be dissolved with the amphiphilic solvent phase make polymer solution, make after miscible with medicine then, be fruit jelly shape, paste or ointment isogel type; The solution-type slow releasing injection can be selected vegetable oil for use, as, but be not limited to, iodine glycerol, certain herbaceous plants with big flowers acid esters, carnic acid, Oleum sesami, Oleum Ricini, Oleum Glycines, Semen arachidis hypogaeae wet goods are made holder; The suspension type slow releasing injection also can be with medicine separately or be packaged in and make oil suspension after the high molecular polymer, medicine and macromolecular compound be combined into the indissoluble salt suspensoid or with the suspension of medicine and reactant salt formation drug salts crystalline solid.
Slow-releasing anticarcinogen injection of the present invention is intracavitary administration agent, intratumor injection agent, all injections of tumor or selective arterial injection, and intracavitary administration comprises in intraperitoneal, the thoracic cavity and injection through vertebral canal.It can also be in the lymph node and the interior injection of bone marrow.
Because the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, the present invention can use simultaneously with non-operative treatment, also can use in non-operative treatment is implemented a few days ago, and its purpose is to strengthen as far as possible the sensitivity of tumor.
Route of administration
Route of administration depends on multiple factor, for obtaining valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in the intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), tumor, in all, the selective arterial injection of tumor, lymph node and place in the bone marrow or injection.With in selective arterial, intracavity, the tumor, tumor week injection serves as preferred.
Dosage
Amount of drug depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.The effective dose of cancer therapy drug is 0.01-200 milligram/kg body weight, is ideal with 1-30 milligram/kg body weight, with 2-20 milligram/kg body weight for the most desirable.Wherein the content of active ingredient is decided because of different needs.Can be good with 1%-50% from 1%-80%, be best with 5%-40%.
The present invention can be used to prepare the slow releasing injection of the various tumors for the treatment of people and animal, and the indication tumor comprises former of originating from nervous system, digestive system, respiratory system, urinary system, reproductive system and skin etc. or cancer or sarcoma or the carcinosarcoma that shifts.Comprise the cerebral tumor, esophageal carcinoma, hepatocarcinoma, cancer of biliary duct, gastric cancer, pancreas, colon cancer, rectal cancer, pulmonary carcinoma, renal carcinoma, bladder cancer, breast carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, carcinoma of prostate, tumor of head and neck, oral cancer, thyroid carcinoma, skin carcinoma, osseous tissue tumor, lymphoma, hemangioma, eyes tumor, retinoblastoma and nasopharyngeal carcinoma.
Also can add other medicinal ingredient in the made slow releasing injection of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
The present invention is a holder with the bio-capacitivity material mainly, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.
The characteristics of technology of preparing of the present invention are according to a certain percentage the anticancer effective component taxine kind anti-cancer to be packaged in the slow-release auxiliary material, use mixing, fusion, dissolving, spray drying, freezing (drying) pulverized, method such as emulsifying or liposome prepares microsphere (or grain), microsphere is used to prepare above-mentioned various slow releasing injection, suspension type slow releasing injection most preferably wherein, the slow-releasing system that suspends or be called the injection anticancer medicine slow-release preparation containing with the injection system, the one, the sustained-release microparticle packing after suspending agent mixes with pastille is suspended in it in common solvent before injection; The 2nd, the sustained-release microparticle of pastille is packed separately, before injection, it is suspended in the special solvent.Special solvent is the common solvent that contains suspending agent.
Below by test and embodiment technical scheme of the present invention is further described.
(4) specific embodiment
The present invention is processed into slow-releasing anticarcinogen injection and further is illustrated by following examples, but is not limited thereto.In the following example the content of component except that have show especially all be weight percentage.
Embodiment 1.
80mg pharmaceutic adjuvant ethylene vinyl acetate copolymer (EVAc) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 20mg nocodazole, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is made the slow-release pill of the nocodazole that contains percentage by weight 20%, ray sterilizing after the packing with fusion method.Slow-release pill is suspended in the water for injection that contains 1.5% sodium carboxymethyl cellulose, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 14-24 days, and the drug release time in mouse breast cancer is 20-35 days.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that contained anticancer effective component is:
Percentage by weight is 30% cytochalasin, Datelliptium Chloride, ellipticine, 2-Methylellipticine, mitoclomine, mitoflaxone, mitoguazone, mitonafide, mitopodozide, mitoquidone, mitosper, mitotane, mitotenamine, mitozolomide, Flavone acetic acid, Salicylate, colchiceinamide, colchicine, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, B cytochalasin B, carbaryl, naphthols, alpha-Naphthol, betanaphthol, the alpha-phosphate naphthols, acodazole, procodazole, giracodazole, nocodazole or malonic acid (salt)
Embodiment 3.
With the 80mg molecular weight is that 20000 PLGA (copolymer of hydroxyacetic acid and glycolic, ratio are 75: 25) puts into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 20mg B cytochalasin B, shake up the dry organic solvent of removing of final vacuum again.Make to such an extent that contain the slow-release pill of percentage by weight 20% B cytochalasin B, packing after ray sterilizing with fusion method dried solid composite.Slow-release pill is suspended in the water for injection that contains 1.5% carboxymethyl cellulose and 15% mannitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 14-24 days, and the drug release time in rat liver cancer is 20-35 days.
Embodiment 4.
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that contained anticancer effective component is: percentage by weight is 40% colchicine, Salicylate, colchiceinamide, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, B cytochalasin B, carbaryl, naphthols, alpha-Naphthol, betanaphthol, the alpha-phosphate naphthols, acodazole, procodazole, giracodazole, nocodazole or malonic acid (salt).
Embodiment 5.
80mg pharmaceutic adjuvant polifeprosan (to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 80: 20) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 20mg colchicine and shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is made the slow-release pill that contains percentage by weight 10% colchicine with fusion method, ray sterilizing after the packing.Slow-release pill is suspended in the water for injection that contains 1.5% carboxymethyl cellulose (sodium) and/or 15% mannitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 14-24 days, and the drug release time in mice lung cancer is 20-30 days.
Embodiment 6.
With 80mg molecular weight peak value 35000 polylactic acid (PLGA70; 30) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add the 20mg Colchicine, shake up the back becomes to contain 20% Colchicine with spray drying method for preparation microsphere again.Microsphere is suspended in the water for injection that contains 1.0% carboxymethyl cellulose (sodium) and/or 10% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this microsphere of this slow releasing injection in external normal saline is 10-50 days, and the drug release time in mouse pancreas cancer is 20-30 days.
Embodiment 7.
With 80mg molecular weight peak value 35000 polylactic acid (PLGA70; 30) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add the 20mg giracodazole, shake up the back becomes to contain 20% giracodazole with spray drying method for preparation microsphere again.Microsphere is suspended in contains in the dehydrated alcohol, make corresponding suspension type slow releasing injection.The drug release time of this suspension type slow releasing injection in external normal saline is 10-50 days, and the drug release time in the mice Subcutaneous tumor is 20-28 days.
Embodiment 8.
With 70mg molecular weight peak value 35000 polylactic acid (PLGA50; 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add the 30mg acodazole, shake up the dry organic solvent of removing of final vacuum again.The bead that contains 30% acodazole is made in dried pastille solids freezing (drying) pulverizing.Microsphere is suspended in contains in the dehydrated alcohol, make corresponding suspension type slow releasing injection.The drug release time of this agent in external normal saline is 15-20 days, and the drug release time in the mice renal carcinoma is 30-38 days.
Embodiment 9.
The method step that is processed into slow-releasing anticarcinogen injection is identical with embodiment 1-8, but different is used slow-release auxiliary material is one of following or its combination:
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,10000-20000,20000-35000 or 30000-50000 and the copolymer of hydroxyacetic acid (PLGA), and wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-5;
C) ethylene vinyl acetate copolymer (EVAc);
D) weight ratio 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) copolymer (polifeprosan);
E) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
Embodiment 10.
The method step that is processed into slow-releasing anticarcinogen injection is identical with embodiment 1-9, but different is used suspending agent is one of following or its combination:
A) 2.5% carboxymethyl cellulose, sodium carboxymethyl cellulose;
B) 10% mannitol;
C) 15% sorbitol;
D) 0.5% polysorbas20
E) glycerol, iodine glycerol, simethicone, propylene glycol or carbomer.
Embodiment 11.
Sustained-release micro-spheres prepared in embodiment 2 or 4 is suspended in the water for injection that contains 1.5% sodium carboxymethyl cellulose and 15% mannitol, makes be weight percentage 30% or 40% colchicine of the contained anticancer effective component of corresponding suspension type slow releasing injection, Salicylate, colchiceinamide, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, B cytochalasin B, carbaryl, naphthols, alpha-Naphthol, betanaphthol, the alpha-phosphate naphthols, acodazole, procodazole, giracodazole, nocodazole, malonic acid or malonate.
As mentioned above, the preparation method of slow-releasing anticarcinogen injection of the present invention can be selected as the case may be.Therefore, above embodiment only is used for explanation and is not limitation application of the present invention.
Tumor-inhibiting action in the body of embodiment 12. anti-mitosis medicine slow releasing injection
With the white mice is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 7 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd to 4 group is colchicine, and the 5th to 7 group is nocodazole, and the 8th to 10 group is alpha-Naphthol.Medicine is respectively through lumbar injection injection (ip), intratumor injection injection (it) and intratumor injection slow releasing agent (itp).Colchicine, nocodazole and alpha-Naphthol all are selected from embodiment 11, and the percentage by weight of medicine in slow releasing agent is respectively 10%, 20% and 30%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 10th day.
Table 1
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 60.5±10.5 | |
| 2(6) | Colchicine (ip) | 24±5.0 | ＜0.05 |
| 3(6) | Colchicine (it) | 14±3.5 | ＜0.01 |
| 4(6) | Colchicine (itp) | 10±1.8 | ＜0.01 |
| 5(6) | Nocodazole (ip) | 22±4.3 | ＜0.01 |
| 6(6) | Nocodazole (it) | 16±4.6 | ＜0.01 |
| 7(6) | Nocodazole (itp) | 10±1.6 | ＜0.001 |
| 8(6) | Alpha-Naphthol (ip) | 20±2.6 | ＜0.001 |
| 9(6) | Alpha-Naphthol (it) | 14±1.6 | ＜0.001 |
| 10(6) | Alpha-Naphthol (itp) | 5±0.6 | ＜0.001 |
Tumor-inhibiting action in the body of embodiment 13. anti-mitosis medicine slow releasing injection.
EXPERIMENTAL DESIGN is with embodiment 12, and the nocodazole of local injection agent, betanaphthol and B cytochalasin B all are selected from embodiment 4, and the percentage by weight of medicine in injection is respectively 10%, 20% and 30% (seeing Table 2).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd to 4 group is nocodazole, and the 5th to 7 group is betanaphthol, and the 8th to 10 group is B cytochalasin B.Medicine is respectively through lumbar injection injection (ip), intratumor injection injection (it) and intratumor injection slow releasing agent (itp).The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 2) on the 10th day.
Table 2
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 76±13 | |
| 2(6) | Nocodazole (ip) | 45±6.2 | ＜0.05 |
| 3(6) | Nocodazole (it) | 38±4.0 | ＜0.01 |
| 4(6) | Nocodazole (itp) | 28±2.6 | ＜0.01 |
| 5(6) | Betanaphthol (ip) | 54±6.0 | ＜0.01 |
| 6(6) | Betanaphthol (it) | 32±3.2 | ＜0.01 |
| 7(6) | Betanaphthol (itp) | 18±2.2 | ＜0.001 |
| 8(6) | B cytochalasin B (ip) | 53±5.8 | ＜0.001 |
| 9(6) | B cytochalasin B (it) | 22±3.0 | ＜0.001 |
| 10(6) | B cytochalasin B (itp) | 10±1.6 | ＜0.001 |
Tumor-inhibiting action in the body of embodiment 14. anti-mitosis medicine slow releasing injection
EXPERIMENTAL DESIGN is with embodiment 12, and the medicine of local injection is that 10% naphthols, 20% giracodazole and 30% mitotenamine are all from embodiment 11.First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd to 4 group is naphthols, and the 5th to 7 group is giracodazole, and the 8th to 10 group is mitotenamine.Medicine is respectively through lumbar injection injection (ip), intratumor injection injection (it) and intratumor injection slow releasing agent (itp).The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 10th day.
Table 3
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 74±10 | |
| 2(6) | Naphthols (ip) | 48±6.6 | ＜0.05 |
| 3(6) | Naphthols (it) | 39±4.1 | ＜0.01 |
| 4(6) | Naphthols (itp) | 28±2.2 | ＜0.01 |
| 5(6) | Giracodazole (ip) | 54±7.0 | ＜0.01 |
| 6(6) | Giracodazole (it) | 36±3.0 | ＜0.01 |
| 7(6) | Giracodazole (itp) | 17±2.2 | ＜0.001 |
| 8(6) | Mitotenamine (ip) | 42±6.6 | ＜0.001 |
| 9(6) | Mitotenamine (it) | 20±2.6 | ＜0.001 |
| 10(6) | Mitotenamine (itp) | 12±1.6 | ＜0.001 |
The result of embodiment 12 to 14 shows that used various anti-mitosis medicines all have the obvious suppression effect to growth of tumour cell when this concentration, but comparatively obvious with local application's effect, and wherein local injection is that the intratumor injection slow releasing agent is the most effective.Local injection not only can suppress tumor growth effectively, and can significantly reduce the general toxic reaction of medicine, and is particularly easy to operate, and local complication (as hemorrhage, infection etc.) is few, and is little to patient's damage, more can not stimulate the tumor diffusion and shifts.
The above unique and significant superiority of slow releasing injection of the present invention has remedied the deficiencies in the prior art, has constituted main feature of the present invention simultaneously.
The preparation of embodiment 15. suspension type slow releasing injection
The method step that is processed into slow-releasing anticarcinogen injection is identical with embodiment 1-11, but different is that its component is as follows:
(A) 10mg colchicine, 90mg polylactic acid (molecular weight peak value 30000), 1mg sodium carboxymethyl cellulose; Or
(B) 20mg colchicine, 80mg polylactic acid (molecular weight peak value 30000), 10ml NaCL injection; Or
(C) 30mg colchicine, 70mg polylactic acid (molecular weight peak value 30000), 1mg sodium carboxymethyl cellulose, 10mlNaCL injection; Or
(D) 10mg acodazole, 40mg polylactic acid (molecular weight peak value 30000), the copolymer of 40mg glycolic and hydroxyacetic acid (molecular weight peak value 30000,75: 25), the 1mg carboxymethyl cellulose; Or
(E) 20mg acodazole, 40mg polylactic acid (molecular weight peak value 30000), 40mg ethylene vinyl acetate copolymer, 10ml dehydrated alcohol; Or
(F) 30mg acodazole, the copolymer of 35mg glycolic and hydroxyacetic acid (molecular weight peak value 30000, weight ratio 75: 25), 35mg ethylene vinyl acetate copolymer, 1mg carboxymethyl cellulose, 10ml dehydrated alcohol.
The above unique and significant superiority of slow releasing injection of the present invention has remedied the deficiencies in the prior art, has constituted main feature of the present invention simultaneously.
Claims (11)
1. a slow-releasing anticarcinogen injection is characterized in that, comprises sustained-release microparticle, suspending agent and/or solvent, and sustained-release microparticle is made up of 1%-80% anti-mitosis medicine and 20-99% slow-release auxiliary material, all is weight percentage.
2. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that described anti-mitosis medicine is selected from cytochalasin, Datelliptium Chloride, ellipticine, 2-Methylellipticine, mitoclomine, mitoflaxone, mitoguazone, mitonafide, mitopodozide, mitoquidone, mitosper, mitotane, mitotenamine, mitozolomide, Flavone acetic acid, colchicine, Salicylate, colchiceinamide, colchicine, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, 7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo[a, sulfo--colchicine, Demecolcine, Colchiceinamidum, Colchicine, B cytochalasin B, carbaryl, naphthols, alpha-Naphthol, betanaphthol, the alpha-phosphate naphthols, acodazole, procodazole, giracodazole, nocodazole, one of malonic acid or malonate or its combination.
3. the described slow-releasing anticarcinogen injection of claim 1, it is characterized in that, described slow-release auxiliary material is selected from one of mixture, ethylene vinyl acetate copolymer, poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid), xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin and white tempera of the copolymer of copolymer, polylactic acid and the glycolic of polylactic acid, polyglycolic acid, glycolic and hydroxyacetic acid and hydroxyacetic acid or its combination.
4. the described slow-releasing anticarcinogen injection of claim 1 is characterized in that, described slow-release auxiliary material is one of following or its combination:
A) molecular weight is the polylactic acid of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the glycolic of 5000-15000,10000-20000,20000-35000 or 30000-50000 and the copolymer of hydroxyacetic acid, and wherein, the weight ratio of glycolic and hydroxyacetic acid is 10: 90-90: 10;
C) ethylene vinyl acetate copolymer;
D) weight ratio 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid copolymer;
E) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
5. slow-releasing anticarcinogen injection according to claim 1, it is characterized in that described suspending agent is selected from one of carboxymethyl cellulose, sodium carboxymethyl cellulose, glycerol, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, polysorbas20 or Tween 80 or its combination.
6. slow-releasing anticarcinogen injection according to claim 1, it is characterized in that, component is 20mg anti-mitosis medicine, 80mg slow-release auxiliary material and 1mg suspending agent, and wherein, anti-mitosis medicine is for being colchicine, acodazole, procodazole, giracodazole or nocodazole; Slow-release auxiliary material is one of copolymer, ethylene vinyl acetate copolymer and polifeprosan of polylactic acid, glycolic and hydroxyacetic acid or its combination; Suspending agent is selected from one of carboxymethyl cellulose, sodium carboxymethyl cellulose, glycerol, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, polysorbas20 or Tween 80 or its combination.
7. slow-releasing anticarcinogen injection according to claim 1, it is characterized in that, component is 30mg anti-mitosis medicine, 70mg slow-release auxiliary material and 10ml solvent, and wherein, anti-mitosis medicine is for being colchicine, acodazole, procodazole, giracodazole or nocodazole; Slow-release auxiliary material is one of copolymer, ethylene vinyl acetate copolymer and polifeprosan of polylactic acid, glycolic and hydroxyacetic acid or its combination; Solvent is selected from distilled water, water for injection, physiology towards liquid, dehydrated alcohol, phosphate or carbonate buffer solution.
8. slow-releasing anticarcinogen injection according to claim 1, it is characterized in that, component is 20mg anti-mitosis medicine, 80mg slow-release auxiliary material, 2mg suspending agent and 10ml solvent, and wherein, anti-mitosis medicine is colchicine, acodazole, procodazole, giracodazole or nocodazole; Slow-release auxiliary material is one of copolymer, ethylene vinyl acetate copolymer and polifeprosan of polylactic acid, glycolic and hydroxyacetic acid or its combination; Solvent is selected from distilled water, water for injection, physiology towards liquid, dehydrated alcohol, phosphate or carbonate buffer solution.
9. as the slow-releasing anticarcinogen injection as described in claim 1 or 2 or 3 or 5, it is characterized in that component is as follows:
(A) 10mg colchicine, 90mg polylactic acid, 1mg sodium carboxymethyl cellulose; Or
(B) 20mg colchicine, 80mg polylactic acid, 10ml NaCL injection; Or
(C) 30mg colchicine, 70mg polylactic acid, 1mg sodium carboxymethyl cellulose+10ml NaCL injection; Or
(D) 10mg acodazole, 40mg polylactic acid, the copolymer of 40mg glycolic and hydroxyacetic acid, 1mg carboxymethyl cellulose; Or
(E) 20mg acodazole, 40mg polylactic acid, 40mg ethylene vinyl acetate copolymer, 10ml dehydrated alcohol; Or
(F) 30mg acodazole, the copolymer of 35mg glycolic and hydroxyacetic acid, 35mg ethylene vinyl acetate copolymer, 1mg carboxymethyl cellulose, 10ml dehydrated alcohol;
Above-mentioned polylactic acid molecule amount peak value 30000, the molecular weight of copolymer peak value 30000 of glycolic and hydroxyacetic acid, blend weight ratio 75: 25, ethylene vinyl acetate copolymer molecular weight peak value 30000.
10. slow-releasing anticarcinogen injection according to claim 1 is characterized in that, is intracavitary administration agent, intratumor injection agent, all injections of tumor or selective arterial injection.
11. the slow-releasing anticarcinogen injection that claim 1 is described, it is characterized in that, be used to prepare the slow releasing injection of the cerebral tumor, esophageal carcinoma, hepatocarcinoma, cancer of biliary duct, gastric cancer, pancreas, colon cancer, rectal cancer, pulmonary carcinoma, renal carcinoma, bladder cancer, breast carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, carcinoma of prostate, tumor of head and neck, oral cancer, thyroid carcinoma, skin carcinoma, osseous tissue tumor, lymphoma, hemangioma, eyes tumor, retinoblastoma and the nasopharyngeal carcinoma for the treatment of people and animal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510044519 CN1748671A (en) | 2005-08-30 | 2005-08-30 | Slow releasing injection containing anti-mitosis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510044519 CN1748671A (en) | 2005-08-30 | 2005-08-30 | Slow releasing injection containing anti-mitosis medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1748671A true CN1748671A (en) | 2006-03-22 |
Family
ID=36604450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510044519 Pending CN1748671A (en) | 2005-08-30 | 2005-08-30 | Slow releasing injection containing anti-mitosis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1748671A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716486A (en) * | 2012-05-07 | 2012-10-10 | 关玫 | Slowly-releasing anticancer drug composition and application thereof |
| WO2019149884A1 (en) * | 2018-02-02 | 2019-08-08 | Murray & Poole Enterprises, Ltd | Use of colchicine to inhibit tumor growth and metastases |
| CN111150702A (en) * | 2019-12-04 | 2020-05-15 | 复旦大学 | Gel drug sustained release preparation and preparation method and application thereof |
| CN114073666A (en) * | 2020-08-11 | 2022-02-22 | 武汉科福新药有限责任公司 | Nadolol slow release injection and preparation method thereof |
| US11648206B2 (en) | 2013-04-16 | 2023-05-16 | Murray And Poole Enterprises Ltd | Sustained-release formulations of colchicine and methods of using same |
-
2005
- 2005-08-30 CN CN 200510044519 patent/CN1748671A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716486A (en) * | 2012-05-07 | 2012-10-10 | 关玫 | Slowly-releasing anticancer drug composition and application thereof |
| CN102716486B (en) * | 2012-05-07 | 2013-11-06 | 关玫 | Slowly-releasing anticancer drug composition and application thereof |
| US11648206B2 (en) | 2013-04-16 | 2023-05-16 | Murray And Poole Enterprises Ltd | Sustained-release formulations of colchicine and methods of using same |
| WO2019149884A1 (en) * | 2018-02-02 | 2019-08-08 | Murray & Poole Enterprises, Ltd | Use of colchicine to inhibit tumor growth and metastases |
| CN111954524A (en) * | 2018-02-02 | 2020-11-17 | 默里和普尔企业有限公司 | Application of colchicine in inhibiting tumor growth and metastasis |
| US11534415B2 (en) | 2018-02-02 | 2022-12-27 | Murray And Poole Enterprises Ltd | Use of colchicine to inhibit tumor growth and metastases |
| US11877991B2 (en) | 2018-02-02 | 2024-01-23 | Murray And Poole Enterprises Ltd | Use of colchicine to inhibit tumor growth and metastases |
| CN111150702A (en) * | 2019-12-04 | 2020-05-15 | 复旦大学 | Gel drug sustained release preparation and preparation method and application thereof |
| CN111150702B (en) * | 2019-12-04 | 2021-06-22 | 复旦大学 | Gel drug sustained release preparation and preparation method and application thereof |
| CN114073666A (en) * | 2020-08-11 | 2022-02-22 | 武汉科福新药有限责任公司 | Nadolol slow release injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1923189A (en) | Taxine kind anti-cancer slow release injection | |
| CN1748671A (en) | Slow releasing injection containing anti-mitosis medicine | |
| CN1923282B (en) | Anti-cancer slow release injection comprising hormone drug | |
| CN1857221A (en) | Slow released anticancer medicien containing both platinum compound and its synergist | |
| CN1824319A (en) | Hormone kind anticancer medicine slow release agent | |
| CN1868453A (en) | Slow-release injection contg. platinum compounds and cellulotoxic medicines | |
| CN1861054A (en) | Composite slow-releasing anticarcinogen contg. platinum compounds such as sunpla | |
| CN1861053A (en) | Slow-releasing injection contg. platinum compounds and cytotoxin type anticarcinogen | |
| CN1861052A (en) | Slow-releasing injection contg. platinum compound and cytotoxin type anticarcinogen | |
| CN1824314A (en) | Slow release agent containing hormone kind anti cancer medicine | |
| CN1923281B (en) | Anti-cancer slow release injection comprising plant alkaloid | |
| CN1923280A (en) | Anti-cancer slow release injection containing dichloroethylaminum | |
| CN1304054C (en) | Combination of slow released anticancer medication | |
| CN1839843A (en) | Fluorouracil slow release injection | |
| CN1957923A (en) | A kind of controlled release injection of carried fluorouracil and synergis | |
| CN1875935A (en) | A sustained release anticancer agent containing clorfarabine and cytotoxic drug | |
| CN1299774C (en) | Slow released anticancer combination of medication embedded the interior of the body | |
| CN1311872C (en) | Anticancer combination of medication | |
| CN1676165A (en) | In vivo slow-releasing anticancer medicinal composition | |
| CN1857215A (en) | Slow released injection containing antimetabolite | |
| CN1634017A (en) | Pharmaceutical composition for solid tumour | |
| CN1887264A (en) | Slow released compound anticancer prepn containing bendamustine | |
| CN1299674C (en) | Slow released combination of anticancer drugs embedded in vivo | |
| CN1957919A (en) | Controlled release agent of containing fluorouracil and synergist | |
| CN101040865A (en) | Sustained-released injection including antimetabolite medicine and alkylate agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |